DOCSLIB.ORG

Download the PDF Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download the PDF Here The new england journal of medicine Original Article Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus The ASCEND Study Collaborative Group*​​ ABSTRACT BACKGROUND Increased intake of n−3 fatty acids has been associated with a reduced risk of car- The members of the writing committee diovascular disease in observational studies, but this finding has not been confirmed (Louise Bowman, M.D., Marion Mafham, M.D., Karl Wallendszus, M.Sc., Will Stevens, in randomized trials. It remains unclear whether n−3 (also called omega-3) fatty Ph.D., Georgina Buck, M.Sc., Jill Barton, acid supplementation has cardiovascular benefit in patients with diabetes mellitus. Kevin Murphy, Theingi Aung, M.D., Rich- ard Haynes, D.M., Jolyon Cox, D.Phil., METHODS Aleksandra Murawska, M.Sc., Allen Young, Ph.D., Michael Lay, D.Phil., Fang We randomly assigned 15,480 patients with diabetes but without evidence of ath- Chen, M.D., Ph.D., Emily Sammons, erosclerotic cardiovascular disease to receive 1-g capsules containing either n−3 fatty M.B., Ch.B., Emma Waters, M.B., B.S., acids (fatty acid group) or matching placebo (olive oil) daily. The primary outcome was Amanda Adler, M.D., Ph.D., Jonathan Bo- dansky, M.D., Andrew Farmer, D.M., a first serious vascular event (i.e., nonfatal myocardial infarction or stroke, transient Roger McPherson, B.M., F.R.C.Ophth., ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage). Andrew Neil, D.Sc., F.R.C.P., David Simp- The secondary outcome was a first serious vascular event or any arterial revascu- son, Richard Peto, F.R.S., F.Med.Sci., Co- lin Baigent, F.F.P.H., F.R.C.P., Rory Collins, larization. F.R.S., F.Med.Sci., Sarah Parish, D.Phil., and Jane Armitage, F.R.C.P., F.F.P.H.) as- RESULTS sume responsibility for the overall con- During a mean follow-up of 7.4 years (adherence rate, 76%), a serious vascular event tent and integrity of this article. The affili- occurred in 689 patients (8.9%) in the fatty acid group and in 712 (9.2%) in the ations of the members of the writing committee are listed in the Appendix. placebo group (rate ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; P = 0.55). Address reprint requests to Dr. Bowman The composite outcome of a serious vascular event or revascularization occurred in at the Medical Research Council, Popula- 882 patients (11.4%) and 887 patients (11.5%), respectively (rate ratio, 1.00; 95% CI, tion Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies 0.91 to 1.09). Death from any cause occurred in 752 patients (9.7%) in the fatty acid Unit, Nuffield Department of Population group and in 788 (10.2%) in the placebo group (rate ratio, 0.95; 95% CI, 0.86 to 1.05). Health, Richard Doll Bldg., Old Road There were no significant between-group differences in the rates of nonfatal seri- Campus, Roosevelt Dr., Oxford OX3 7LF, United Kingdom, or at ascend@ ndph . ox . ous adverse events. ac . uk or louise . bowman@ ndph . ox . ac . uk. CONCLUSIONS *A complete list of the members of the ASCEND Study Collaborative Group is Among patients with diabetes without evidence of cardiovascular disease, there was provided in Supplementary Appendix 1, no significant difference in the risk of serious vascular events between those who available at NEJM.org. were assigned to receive n−3 fatty acid supplementation and those who were as- This article was published on August 26, signed to receive placebo. (Funded by the British Heart Foundation and others; 2018, at NEJM.org. Current Controlled Trials number, ISRCTN60635500; ClinicalTrials.gov number, DOI: 10.1056/NEJMoa1804989 NCT00135226.) Copyright © 2018 Massachusetts Medical Society. n engl j med nejm.org 1 The New England Journal of Medicine Downloaded from nejm.org by JULES LEVIN on August 26, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved. The new england journal of medicine bservational studies in different findings that are now reported elsewhere in the populations have suggested that fish con- Journal.17 sumption once or twice a week is associ- O 1,2 ated with a reduced risk of heart disease. In 2002, Methods a systematic review concluded that eating the equivalent of 40 to 60 g of fish daily (providing Trial Oversight about 0.2 to 1.0 g of n−3 fatty acids) was associ- ASCEND was designed and conducted by inde- ated with nearly a 50% reduction in cardiovascular pendent investigators in the Clinical Trial Service mortality.3 However, randomized trials of supple- Unit at the University of Oxford (the regulatory mentation with n−3 (also called omega-3) fatty trial sponsor). The trial methods, patient charac- acids have shown conflicting results regarding the teristics, and data analysis plan (including out- effects on fatal or nonfatal outcomes.4-8 Meta- come definitions) have been reported previous- analyses of these trials have generally not identi- ly.18,19 The protocol (available with the full text of fied significant beneficial effects of n−3 fatty acid this article at NEJM.org) was approved by the supplementation on major vascular events.9,10 North West Multicenter Research Ethics Commit- However, interest has persisted about possible tee. The trial was funded by the British Heart benefits with respect to particular types of vascu- Foundation. Capsules containing the n−3 fatty lar events (including arrhythmias, heart failure, acids and matching placebo (along with funding and death from coronary heart disease) on the for packaging) were provided by Mylan (and for- basis, at least in part, of selected results in open- merly by Solvay and Abbott), and Bayer provided label trials.4,11,12 A recent meta-analysis10 was con- the aspirin and placebo. Mylan, Solvay, and Abbott ducted of 10 long-term, randomized trials of n−3 had nonvoting representation at meetings of the fatty acids as either primary or secondary pre- steering committee and provided comments re- vention in a total of 78,000 participants, includ- garding the trial design and draft manuscript ing approximately one third with diabetes or dys- but otherwise had no role in data collection or glycemia who were enrolled mainly in two large analysis or in the decision to submit the manu- trials.8,13 During a mean follow-up of 4.4 years, script for publication. the meta-analysis did not show significantly lower The manuscript was prepared by the writing rates of coronary heart disease or major vascular committee and was reviewed and approved for events among the patients who had received n−3 submission by the steering committee. The first fatty acids than among those in the control groups. and last members of the writing committee vouch The American Heart Association guidelines for the completeness and accuracy of the data and currently recommend n−3 fatty acid supplements analyses, and for the fidelity of the trial to the for secondary prevention of coronary heart dis- study protocol and data analysis plan. Requests ease,14 and fish consumption for primary preven- for data sharing will be handled in line with the tion is recommended in cardiovascular disease data access and sharing policy of the Nuffield prevention guidelines.15 Since patients with dia- Department of Population Health, University of betes have two to three times the risk of cardio- Oxford (available at www . ndph . ox . ac . uk/ about/ vascular disease as the general population,16 a data - access - policy). safe dietary supplement with even a modest protec- tive effect could have a major public health benefit. Patients We performed the randomized ASCEND Men and women who were at least 40 years of (A Study of Cardiovascular Events in Diabetes) to age (without an upper age limit) were considered assess the efficacy and safety of daily supplemen- eligible if they had received a diagnosis of diabe- tation with n−3 fatty acids, as compared with tes mellitus (any type) but did not have evidence placebo, in patients with diabetes without evi- of cardiovascular disease. Key exclusion criteria dence of cardiovascular disease at trial entry. Us- were a clear indication or contraindication for the ing a factorial design in the same trial, we also receipt of n−3 fatty acids or (with respect to the randomly assigned the patients to receive a daily factorial design, reported separately) aspirin or regimen of either 100 mg of aspirin or placebo, other condition that might limit adherence to at 2 n engl j med nejm.org The New England Journal of Medicine Downloaded from nejm.org by JULES LEVIN on August 26, 2018. For personal use only. No other uses without permission. Copyright © 2018 Massachusetts Medical Society. All rights reserved. n−3 Fatty Acid Supplements in Diabetes Mellitus least 5 years of participation in the trial. Patients mean follow-up of 2.5 years, we requested blood who reported the over-the-counter receipt of fish and urine samples, along with measures of blood oil or n−3 fatty acid supplements were asked to pressure and weight, from 1800 randomly selected stop them wherever possible, but they remained patients. (Details are provided in the Methods sec- eligible to participate in the trial, provided that tion of Supplementary Appendix 1, available at the daily dose was less than 1 g. All the patients NEJM.org.) provided written informed consent. Outcomes Procedures While recruitment was still ongoing, we modified Using regional diabetes registers or general prac- the original primary outcome to include transient tice data from around the United Kingdom, we ischemic attack (TIA) in the definition of serious identified potential patients and mailed them a vascular events, a change that was made to in- screening questionnaire.
Load more

Recommended publications
  • Keep Hearts Beating This Christmas
    NOT A MEMBER? JOIN TODAY! November/December 2015 1 Your details Title First name Last name KEEP HEARTS BEATING FREE House name/number Street City/Town County Postcode THIS CHRISTMAS Date of birth Home/work phone Mobile phone PULL OUT Risk factors AND KEEP THE BIG Email explained FREEZE Why are you signing up for Heart Matters membership? Cut your chances RECIPE CARDS For myself Because I’m caring for someone with a heart condition For my work Other (please specify) of heart disease 2 Your Heart Matters membership Please tell us how you would prefer to read your Heart Matters magazine (select one option only). PLUS Magazine delivered to me every two months. Top tips for Online version of Heart Matters magazine every two months (we will send you an email to tell you when the magazine is available online). healthy meals Please ensure you have provided us with a valid email address above. in a hurry In addition to your Heart Matters membership, you can receive a bi-monthly e-newsletter with the latest news from Heart Matters. Tick here to receive it (please ensure you have provided us with a valid email address above). 3 Keeping in touch 10WAYS TO By submitting this form, you agree to us adding your details to our database, so that we can contact you about this matter going forward. We would also like to keep you up to date with news about our work and ways you can get involved. REBUILD YOUR Yes please, I’d like to hear from you by email CONFIDENCE Yes please, I’d like to hear from you by text message or MMS No thank you, please do not contact me by mail Our Christmas cards fund life saving research that keeps more families together at Christmas.
    [Show full text]
  • Estimation of the Optimum Dose of Vitamin D for Disease Prevention in Older People: Rationale, Design and Baseline Characteristics of the BEST-D Trial
    Accepted Manuscript Title: Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial Author: Robert Clarke Connie Newman Joseph Tomson Harold Hin Rijo Kurien Jolyon Cox Michael Lay Jenny Sayer Michael Hill Jonathan Emberson Jane Armitage PII: S0378-5122(15)00030-4 DOI: http://dx.doi.org/doi:10.1016/j.maturitas.2015.01.013 Reference: MAT 6331 To appear in: Maturitas Received date: 3-11-2014 Revised date: 20-1-2015 Accepted date: 27-1-2015 Please cite this article as: Clarke R, Newman C, Tomson J, Hin H, Kurien R, Cox J, Lay M, Sayer J, Hill M, Emberson J, Armitage J, Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial, Maturitas (2015), http://dx.doi.org/10.1016/j.maturitas.2015.01.013 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Highlights The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial will compare the biochemical and other effects of daily dietary supplementation with 100µg or 50µg vitamin D3 or placebo, when administered for 12 months, in 305 ambulant community-dwelling older people living in Oxfordshire, England.
    [Show full text]
  • Faculty Jane Armitage
    Faculty Jane Armitage (Professor of Clinical Trials and Epidemiology, CTSU and Honorary Consultant in Public Health Medicine) Principal investigator for several large trials including HPS, SEARCH and HPS2-THRIVE Co-principal investigator for the ASCEND trial of aspirin and fish oils involving 15,000 people with diabetes http://www.ndph.ox.ac.uk/team/jane-armitage Paul Aveyard (Professor of Behavioural Medicine, Nuffield Department of Primary Care Health Sciences) Principal investigator for randomized trials assessing interventions to help achieve weight loss and smoking cessation Former president of the UK Society of Behavioural Medicine and government advisor on smoking and obesity https://www.phc.ox.ac.uk/team/paul-aveyard Colin Baigent (Professor of Epidemiology and Deputy Director of CTSU) Principal investigator for the 9000 participant Study of Heart and Renal Protection (SHARP) Principal investigator for the Cholesterol Treatment Trialists' (CTT) and Anti-Thrombotic Trialists’ (ATT) Collaborations http://www.ndph.ox.ac.uk/team/colin-baigent Louise Bowman (Associate Professor, CTSU and Honorary Consultant Oxford University Hospitals NHS Foundation Trust) Co-principal investigator for the ASCEND trial and the 30,000 participant international REVEAL study MRC HTMR Executive Committee Member for the MRC CTSU Hub http://www.ndph.ox.ac.uk/team/louise-bowman Richard Bulbulia (Senior Research Fellow, CTSU and Vascular Surgeon Gloucester Hospitals NHS Foundation Trust) Co-principal investigator of ACST-2 (a large trial of endarterectomy
    [Show full text]
  • ASCEND ARRIVE Aspect Trial Updates Aspirin: Science Awards
    Aspirin: Trial Updates Science Awards 2018 ASPREEASCEND AspECT seAFOod ARRIVE Page 2 Aspirin: Trial Updates and Science Awards 2018 Aspirin: Trial Updates and Science Awards 2018 connections, debate, questions and clarity The International Aspirin Foundation’s meeting held at The Royal Society of Edinburgh very much lived up to the motto of this institution; “Knowledge made useful.” In addition to recognising the valuable work of the winners of the Emerging Aspirin Investigator Award and the Senior Science Award, the Principal Investigators from five of the recently completed major aspirin trials (ARRIVE1, ASCEND2, ASPREE3-5, AspECT6 and seAFOod7) presented and discussed their findings. The attendees, an international, multidisciplinary group of scientists and clinicians including professors of neurology, epidemiology, gastroenterology, oncology and pharmacology, gave great value in terms of intense debate and the sharing of knowledge. Pippa Hutchison, Executive Director of the International Aspirin Foundation, gave a warm welcome to attendees and in particular, thanked the Principal Investigators of the recently completed aspirin trials who travelled from as far as Australia in order to be part of this unique meeting. Professor Carlo Patrono, Chair of the Scientific Advisory Board for the International Aspirin Foundation opened the meeting with a poignant step back in time through the pedigree of previous award winners. Professor Patrono dedicated his presentation to the memory of Gustav Born, a good friend and a great scientist, who
    [Show full text]
  • Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial
    EBioMedicine 31 (2018) 133–142 Contents lists available at ScienceDirect EBioMedicine journal homepage: www.ebiomedicine.com Research Paper Genomic Response to Vitamin D Supplementation in the Setting of a Randomized, Placebo-Controlled Trial Antonio J. Berlanga-Taylor a,b,c, Katharine Plant b,AndrewDahlb,EvelynLaub, Michael Hill d,e,DavidSimsa, Andreas Heger a, Jonathan Emberson d,e, Jane Armitage d, Robert Clarke d, Julian C. Knight b,⁎ a Computational Genomics Analysis and Training (CGAT), Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK b Wellcome Centre for Human Genetics (WHG), Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK c MRC-PHE Centre for Environment and Health, Department of Epidemiology & Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK d Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Roosevelt Drive, Oxford OX3 7LF, UK e MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Roosevelt Drive, Oxford OX3 7LF, UK article info abstract Article history: Background: Vitamin D deficiency has been associated with multiple diseases, but the causal relevance and un- Received 16 February 2018 derlying processes are not fully understood. Elucidating the mechanisms of action of drug treatments in humans Received in revised form
    [Show full text]
  • Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac
    ORIGINAL RESEARCH Effects of Vitamin D on Blood Pressure, Arterial Stiffness, and Cardiac Function in Older People After 1 Year: BEST-D (Biochemical Efficacy and Safety Trial of Vitamin D) Joseph Tomson, MRCP; Harold Hin, MRCP; Jonathan Emberson, PhD; Rijo Kurien, MSc; Michael Lay, DPhil; Jolyon Cox, DPhil; Michael Hill, DPhil; Linda Arnold, MSc; Paul Leeson, FRCP; Jane Armitage, FRCP; Robert Clarke, FRCP Background-—The relevance of vitamin D for prevention of cardiovascular disease is uncertain. The BEST-D (Biochemical Efficacy and Safety Trial of vitamin D) trial previously reported effects of vitamin D on plasma markers of vitamin D status, and the present report describes the effects on blood pressure, heart rate, arterial stiffness, and cardiac function. Methods and Results-—This was a randomized, double-blind, placebo-controlled trial of 305 older people living in United Kingdom, who were allocated vitamin D 4000 IU (100 lg), vitamin D 2000 IU (50 lg), or placebo daily. Primary outcomes were plasma concentrations of 25-hydroxy-vitamin D and secondary outcomes were blood pressure, heart rate, and arterial stiffness in all participants at 6 and 12 months, plasma N-terminal prohormone of brain natriuretic peptide levels in all participants at 12 months, and echocardiographic measures of cardiac function in a randomly selected subset (n=177) at 12 months. Mean (SE) plasma 25- hydroxy-vitamin D concentrations were 50 (SE 2) nmol/L at baseline and increased to 137 (2.4), 102 (2.4), and 53 (2.4) nmol/L after 12 months in those allocated 4000 IU/d, 2000 IU/d of vitamin D, or placebo, respectively.
    [Show full text]
  • Aspirin for the Older Person: Report of a Meeting at the Royal Society of Medicine, London, 3Rd November 2011
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011 J Armitage1, J Cuzick2, P Elwood3, M Longley4, A Perkins5, K Spencer6, H Turner7, S Porch8, S Lyness9, J Kennedy10 and GN Henderson11 1Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford 2Professor of Epidemiology. Cancer Research UK 3Director of Primary Care and Public Health, University of Cardiff 4Director, Welsh Institute for Health and Social Care, and Professor of Applied Health Policy, University of Glamorgan 5Professor of Radiological and Imaging Sciences, University of Nottingham Queen’s Medical Centre 6Director of Special Projects, europacolon 7Fellow, Royal Society for Public Health 8Director of Services, Bowel Cancer UK 9Executive Director of Policy and Information, Cancer Research UK 10Director of Operations, europacolon 11Executive Director, Aspirin Foundation, PO Box 223, Haslemere, GU27 3ZJ, United Kingdom Organised by the Aspirin Foundation www.aspirin-foundation.com – sponsored by Bayer Pharma AG/Novacyl Correspondence to: GN Henderson. Email: [email protected] Conference Report Conference Abstract On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was sup- ported by Bayer Pharma AG and Novacyl. Published: 28/02/2012 Received: 18/01/2012 ecancer 2012, 6:245 DOI: 10.3332/ecancer.2012.245 Copyright: © the authors; licensee ecancermedicalscience.
    [Show full text]
  • BEST-D Trial of Vitamin D in Primary Care
    Osteoporos Int DOI 10.1007/s00198-016-3833-y ORIGINAL ARTICLE Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care H. Hin1 & J. Tomson2 & C. Newman3 & R. Kurien2 & M. Lay2 & J. Cox2 & J. Sayer2 & M. Hill2 & J. Emberson2 & J. Armitage2 & R. Clarke2 Received: 2 June 2016 /Accepted: 2 November 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Results Mean (SD) plasma 25(OH)D levels were 50 (18) Summary This trial compared the effects of daily treatment nmol/L at baseline and increased to 137 (39), 102 (25) and with vitamin D or placebo for 1 year on blood tests of vitamin 53 (16) nmol/L after 12 months in those allocated 4000 IU, D status. The results demonstrated that daily 4000 IU vitamin 2000 IU or placebo, respectively (with 88%, 70% and 1% of D3 is required to achieve blood levels associated with lowest these groups achieving the pre-specified level of >90 nmol/L). disease risks, and this dose should be tested in future trials for Neither dose of vitamin D3 was associated with significant fracture prevention. deviation outside the normal range of PTH or albumin- Introduction The aim of this trial was to assess the effects of corrected calcium. The additional effect on 25(OH)D levels daily supplementation with vitamin D3 4000 IU (100 μg), of 4000 versus 2000 IU was similar in all subgroups except for 2000 IU (50 μg) or placebo for 1 year on biochemical markers body mass index, for which the further increase was smaller in of vitamin D status in preparation for a large trial for preven- overweight and obese participants compared with normal- tion of fractures and other outcomes.
    [Show full text]
  • Vitamin D and Calcium for the Prevention of Fracture: A
    Original Investigation | Public Health Vitamin D and Calcium for the Prevention of Fracture A Systematic Review and Meta-analysis Pang Yao, PhD; Derrick Bennett, PhD; Marion Mafham, MD; Xu Lin, MD, PhD; Zhengming Chen, DPhil; Jane Armitage, FRCP; Robert Clarke, FRCP, MD Abstract Key Points Question What is the available IMPORTANCE Vitamin D and calcium supplements are recommended for the prevention of evidence for the efficacy of vitamin D fracture, but previous randomized clinical trials (RCTs) have reported conflicting results, with with or without calcium uncertainty about optimal doses and regimens for supplementation and their overall effectiveness. supplementation for reducing the risk of fracture? OBJECTIVE To assess the risks of fracture associated with differences in concentrations of 25-hydroxyvitamin D (25[OH]D) in observational studies and the risks of fracture associated with Findings This systematic review and supplementation with vitamin D alone or in combination with calcium in RCTs. meta-analysis of randomized clinical trials of vitamin D alone (11 randomized DATA SOURCES PubMed, EMBASE, Cochrane Library, and other RCT databases were searched from clinical trials with 34 243 participants) database inception until December 31, 2018. Searches were performed between July 2018 and showed no significant association with December 2018. risk of any fracture or of hip fracture. In contrast, daily supplementation with STUDY SELECTION Observational studies involving at least 200 fracture cases and RCTs enrolling both vitamin D and calcium (6 at least 500 participants and reporting at least 10 incident fractures were included. Randomized randomized clinical trials with 49 282 clinical trials compared vitamin D or vitamin D and calcium with control.
    [Show full text]
  • Review the Safety of Statins in Clinical Practice
    Review The safety of statins in clinical practice Jane Armitage Statins are eff ective cholesterol-lowering drugs that reduce the risk of cardiovascular disease events (heart attacks, Lancet 2007; 370: 1781–90 strokes, and the need for arterial revascularisation). Adverse eff ects from some statins on muscle, such as myopathy Published Online and rhabdomyolysis, are rare at standard doses, and on the liver, in increasing levels of transaminases, are unusual. June 7, 2007 Myopathy—muscle pain or weakness with blood creatine kinase levels more than ten times the upper limit of the DOI:10.1016/S0140- 6736(07)60716-8 normal range—typically occurs in fewer than one in 10 000 patients on standard statin doses. However, this risk Clinical Trial Service Unit and varies between statins, and increases with use of higher doses and interacting drugs. Rhabdomyolysis is a rarer and Epidemiological Studies Unit, more severe form of myopathy, with myoglobin release into the circulation and risk of renal failure. Stopping statin Oxford, UK (J Armitage FRCP) use reverses these side-eff ects, usually leading to a full recovery. Asymptomatic increases in concentrations of liver Correspondence to: transaminases are recorded with all statins, but are not clearly associated with an increased risk of liver disease. For Dr Jane Armitage, most people, statins are safe and well-tolerated, and their widespread use has the potential to have a major eff ect on Clinical Trial Service Unit and Epidemiological Studies Unit, the global burden of cardiovascular disease. Richard
    [Show full text]
  • PLENARY 4 (PL4): Advances in Lipid-Modification for the Prevention
    PLENARY 4 (PL4): Advances in lipid-modification for the prevention of vascular disease Professor Jane Armitage Jane Armitage is Professor of Clinical Trials and Epidemiology and Honorary Consultant in Public Health Medicine in the Nuffield Department of Population Health (NDPH) at the University of Oxford. She joined the Clinical Trial Service Unit, now part of NDPH, in 1990 from a background in clinical medicine, with particular experience in respiratory medicine, geriatrics and diabetes. She coordinates a series of large-scale clinical trials including the MRC/BHF Heart Protection Study, SEARCH and HPS2-THRIVE, which are trials of lipid modification in people with or at risk of vascular disease, as well as the ASCEND trial of aspirin and fish oils in diabetes. Her main research interests are in lipids and the epidemiology of cardiovascular and other chronic disease including osteoporosis. SUMMARY Objectives : 1. To understand the importance of different lipids to vascular disease risk and how genetics have helped 2. To reiterate the value and safety of statins as a first line therapy for lipid modification 3. To explain the potential role of newer lipid-lowering agents: PCSK9 inhibitors, cholesterol ester transfer protein inhibitors and small interfering RNAs to block lipid-related protein synthesis Observational studies indicate a clear, positive and continuous relationship between coronary heart disease risk and blood LDL- cholesterol levels and inverse associations with HDL-cholesterol. Recent genetic evidence also supports a causal role for CETP, lipoprotein (a) [Lp(a)], apoC3, ANGPLT3 and PCSK9 in vascular risk. Large, well-designed randomized trials of statins and meta-analyses of trials show that reductions of 20-25% in the risk of vascular events are seen per 1 mmol/L reduction in LDL-cholesterol, with larger reductions producing greater benefits.
    [Show full text]
  • Scientific Summary the Statinwise Series of 200 N-Of-1 Rcts Health Technology Assessment 2021; Vol
    The effect of statins on muscle symptoms in primary care: the StatinWISE series of 200 N-of-1 RCTs Emily Herrett,1 Elizabeth Williamson,2 Kieran Brack,3 Alexander Perkins,4 Andrew Thayne,4 Haleema Shakur-Still,4 Ian Roberts,4 Danielle Prowse,4 Danielle Beaumont,4 Zahra Jamal,4 Ben Goldacre,5 Tjeerd van Staa,6 Thomas M MacDonald,7 Jane Armitage,8 Michael Moore,9 Maurice Hoffman10 and Liam Smeeth1* 1Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK 2Department of Medical Statistics, London School of Hygiene & Tropical Medicine, London, UK 3Liver Research, King’s College Hospital, London, UK 4Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK 5Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK 6Division of Informatics, Imaging and Data Sciences, University of Manchester, Manchester, UK 7Medicines Monitoring Unit, School of Medicine, University of Dundee, Dundee, UK 8Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK 9School of Primary Care and Population Sciences, University of Southampton, Southampton, UK 10London, UK *Corresponding author [email protected] Declared competing interests of authors: Liam Smeeth reports grants from the Wellcome Trust, the Medical Research Council (MRC), the National Institute for Health Research (NIHR), GlaxoSmithKline plc (Brentford, UK), British Heart Foundation and Diabetes UK outside the submitted work. Liam Smeeth is also a trustee of the British Heart Foundation. Thomas M MacDonald reports grants and personal fees from Novartis International AG (Basel, Switzerland), Pfizer Inc. (New York, NY, USA) and Menarini (Florence, Italy), grants from Ipsen (Paris, France) and personal fees from Takeda (Tokyo, Japan) outside the submitted work.
    [Show full text]